The coming of the innovation tide in the next decade, only by doing so can pharmaceutical enterprises stand proudly

For China's pharmaceutical industry, the second decade of this century belongs to the era of frequent policies Drug regulatory authorities have turned from SFDA to CFDA and then to nmpa three times, and the national health insurance bureau is the first time established to suppress enterprises in the medical insurance negotiation and access In fact, since the beginning of the new medical reform in 2009, unprecedented changes have taken place in China's pharmaceutical industry, with more systematic industrial policy-making and stronger enforcement No matter in drug approval, production, circulation, payment links or other aspects, the new medical policies proposed by the new governance institutions are directed at the pain points of the industry What we can make sure is that whether it is the pharmaceutical industry or other industries, conforming to the development trend of the times is one of the important factors for a company to be based on its advantageous position In August, McKinsey said in a report that the Chinese pharmaceutical industry is at a critical stage of a new round of development driven by the macro environment If we can seize the precious window of opportunity, the global competitiveness and innovation of Chinese pharmaceutical enterprises will also be greatly improved At present, China's pharmaceutical market continues to grow rapidly, ranking second only to the United States in scale and second in the world The report points out that under the influence of some external factors, the whole industry will have five key turning points in the next few years: 1、 The consistency evaluation of generic drugs and the reform of medical insurance put pressure on the price of mature products, but they may bring more sufficient financial support for innovative products and promote the maturity of China's market; 2、 Many pharmaceutical enterprises regard innovative drugs as the focus of their future product portfolio, and the realization of the value of innovative products will be affected by the access and medical insurance negotiation; 3、 The Chinese market has gradually become the strategic center of pharmaceutical enterprises; 4、 With the continuous expansion of the market, biomedical enterprises are eager for talents; 5、 Digitalization has not fundamentally changed the pharmaceutical industry, but digital communication mode has become increasingly common The above five points will become an important direction for the development of China's pharmaceutical industry in the next decade After all, for enterprises, interpretation of the future development trend can make them better move forward, based on the dominant position In fact, China's pharmaceutical innovation ecosystem has changed significantly in the past three years, and enterprises' sensitive sense of smell will not make them wait for death In the past decade, great progress has been made Of course, due to the continuous improvement of pharmaceutical industry technology, some enterprises, such as many API enterprises, have not kept up with the trend However, the surviving enterprises began to learn the advanced management concepts of foreign pharmaceutical enterprises, and gradually walked out of a number of industry-leading enterprises by exchanging learning for opportunities, cost for market, innovation for recognition and speed for capital For example, in the past decade, a number of mainland new biological enterprises, including Baiji Shenzhou, Junshi biology, Xinda biology and Geli pharmaceutical, have gradually emerged, and gradually represent the development direction of China's innovative pharmaceutical enterprises Other old brand pharmaceutical enterprises, such as Hengrui pharmaceutical, Zhengda Tianqing pharmaceutical and Fosun Pharmaceutical, have also changed from pure generic R & D to innovative drug R & D This is because the enterprise wants to take the initiative to make a difference, and it is also forced by the environment Due to the impact of volume purchase, medical insurance negotiation and access, the profit space of generic drugs has gradually decreased in the future, which forces the enterprise to transform to innovation driven And it can be predicted that those drug companies driven by R & D will be more popular with market investors in the future At this moment, we are standing on the eve of the 1920s In addition to what the recovery experienced in the first decade, what's more important is that we still need to explore the next new era What kind of mentality do we need to use to see the coming of the next moment, which is the expectation? Nervous? Or a long time? In any case, it is extremely important that as an industry greatly affected by policies, pharmaceutical enterprises need to constantly perceive the changes in national policies and comply with the mainstream trend of national innovation and development If they can do this, they will stand proudly in the next decade So, what kind of variables will appear in the next decade in China's pharmaceutical industry? What is the future? Please look forward to the "2019 China Pharmaceutical new wisdom forum" held in Beijing on December 28 At that time, many industry professionals will come with you to have an insight into the new development of China's pharmaceutical industry in the next decade December 28, 2019 Renaissance Beijing wangfujing HOTEL 1860/ people Note: 1 The above attendance fee includes conference service fee, materials, lunch, attendance certificate, etc (excluding accommodation) during the conference; 2 The specially invited guests and members of the medical materials Association enjoy free tickets (excluding accommodation) Scan the QR code below to sign up Tel: 010-61934050-818